Q-omics provides the consensus-scored RPL32P13 profile across patient tissues and cancer cell-line models. RPL32P13 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL32P13 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, RPL32P13 RNA expression shows 6,323 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, UCEC, and STAD as cancer lineages where RPL32P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P13 survival associations across molecular data types. RPL32P13 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P13 RNA expression–survival associations across cancer types. High RPL32P13 expression shows unfavorable associations in LIHC, KIRC and KICH, but favorable associations in SKCM, BLCA and UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL32P13 RNA expression.
This table summarizes RPL32P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL32P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P13 shows lower tumor expression in UCEC and higher tumor expression in PRAD, LUAD, COAD and KIRC. The UCEC box plot shows higher RPL32P13 RNA expression in normal versus tumor tissue (log2 FC = −0.390, t-test p = .002).
This table shows molecular features associated with RPL32P13 in patient tissues and cancer cell lines. In patient samples, RPL32P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
